2026 Q1 -tulosraportti
Vain PDF
83 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenI am somewhat in doubt if TF can handle the task and get Saniona into midcap by November/January (it didn't succeed last year). It seems like something/someone wants to keep the value below the midcap requirement for as long as possible for a reason. Maybe it's easier to manipulate the value when management is silent, so it's a free-for-all for the swindlers.- ·2 päivää sitten · MuokattuI wonder if some shareholders will soon realize something is wrong. Soon a year of silence and it's being paraded around as it suits the swindlers. I wonder if we close at 12.6 today? That silence could well end in a price much lower if something or someone doesn't intervene, tragic that one can push it down 60% on nothing. Now one has to go down to minus 3% to sell a small portion.
·12.8.Saniona is facing an exciting future with all internal study starts, external study starts, and a platform that more or less churns out good candidates. The coming 2-3 years will be very interesting, but also the months.
- ·10.8.0-1% up at close today 🤣🤣🤣🤣
Oh well - it should make a good move up today, on that news, I would think - but alas, the market's ways are unfathomable :) 
·10.8. · MuokattuSaniona has the right to receive development, regulatory, and commercial milestone payments of up to 172 million USD, consisting of up to 97 million USD in development and regulatory milestones and up to 75 million USD in commercial milestones. In addition to this, Saniona has the right to tiered royalty payments on the net sales of the products that AstronauTx commercializes within the framework of the collaboration.
Precisely, and here Redeye writes.... Saniona announced this morning that AstronauTx has exercised its option under the 2023 research collaboration and option agreement, securing "exclusive worldwide rights" to research, develop, manufacture and commercialize therapeutic candidates arising from the collaboration. The program has produced the development candidate ATX0926, which is expected to enter IND-enabling studies shortly and where the aim is, according to AstronauTx, "promoting glymphatic flow as a potential new approach to treating neurological disease." As compensation, Saniona receives shares in AstronauTx with a value of USD5m, priced on the terms of the Series A financing completed in October 2023. Saniona is eligible for milestones of up to USD172m, comprising up to USD97m in development and regulatory milestones and up to USD75m in commercial milestones, in addition to tiered royalties on net sales. Although it has taken some time, it is our view that the exercise is a positive development and a further strong validation of Saniona's ion channel platform. AstronauTx is backed by investors including Novartis Venture Fund, Bristol Myers Squibb and EQT Life Sciences, in other words, very strong backers. Saniona does not receive cash directly at this stage, but it retains the right to significant milestones and royalties should the program advance, and the shareholding gives it a second way to gain value from the collaboration (and potentially other AstronauTx programs). As we have said before, there is considerable value in Saniona's platform, and the company now holds a stake in another interesting venture. We make no immediate change to our valuation at this stage (we currently have a valuation of the collaboration in our SOTP), but will discuss the news and review the implications further in our Q2 update and investor call.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
83 päivää sitten
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenI am somewhat in doubt if TF can handle the task and get Saniona into midcap by November/January (it didn't succeed last year). It seems like something/someone wants to keep the value below the midcap requirement for as long as possible for a reason. Maybe it's easier to manipulate the value when management is silent, so it's a free-for-all for the swindlers.
- ·2 päivää sitten · MuokattuI wonder if some shareholders will soon realize something is wrong. Soon a year of silence and it's being paraded around as it suits the swindlers. I wonder if we close at 12.6 today? That silence could well end in a price much lower if something or someone doesn't intervene, tragic that one can push it down 60% on nothing. Now one has to go down to minus 3% to sell a small portion.
- ·12.8.Saniona is facing an exciting future with all internal study starts, external study starts, and a platform that more or less churns out good candidates. The coming 2-3 years will be very interesting, but also the months.
- ·10.8.0-1% up at close today 🤣🤣🤣🤣Oh well - it should make a good move up today, on that news, I would think - but alas, the market's ways are unfathomable :)
- ·10.8. · MuokattuSaniona has the right to receive development, regulatory, and commercial milestone payments of up to 172 million USD, consisting of up to 97 million USD in development and regulatory milestones and up to 75 million USD in commercial milestones. In addition to this, Saniona has the right to tiered royalty payments on the net sales of the products that AstronauTx commercializes within the framework of the collaboration.Precisely, and here Redeye writes.... Saniona announced this morning that AstronauTx has exercised its option under the 2023 research collaboration and option agreement, securing "exclusive worldwide rights" to research, develop, manufacture and commercialize therapeutic candidates arising from the collaboration. The program has produced the development candidate ATX0926, which is expected to enter IND-enabling studies shortly and where the aim is, according to AstronauTx, "promoting glymphatic flow as a potential new approach to treating neurological disease." As compensation, Saniona receives shares in AstronauTx with a value of USD5m, priced on the terms of the Series A financing completed in October 2023. Saniona is eligible for milestones of up to USD172m, comprising up to USD97m in development and regulatory milestones and up to USD75m in commercial milestones, in addition to tiered royalties on net sales. Although it has taken some time, it is our view that the exercise is a positive development and a further strong validation of Saniona's ion channel platform. AstronauTx is backed by investors including Novartis Venture Fund, Bristol Myers Squibb and EQT Life Sciences, in other words, very strong backers. Saniona does not receive cash directly at this stage, but it retains the right to significant milestones and royalties should the program advance, and the shareholding gives it a second way to gain value from the collaboration (and potentially other AstronauTx programs). As we have said before, there is considerable value in Saniona's platform, and the company now holds a stake in another interesting venture. We make no immediate change to our valuation at this stage (we currently have a valuation of the collaboration in our SOTP), but will discuss the news and review the implications further in our Q2 update and investor call.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
83 päivää sitten
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 27.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 26.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 27.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 28.5.2025 |
0,0823 SEK/osake
Viimeisin osinko
0,00%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenI am somewhat in doubt if TF can handle the task and get Saniona into midcap by November/January (it didn't succeed last year). It seems like something/someone wants to keep the value below the midcap requirement for as long as possible for a reason. Maybe it's easier to manipulate the value when management is silent, so it's a free-for-all for the swindlers.
- ·2 päivää sitten · MuokattuI wonder if some shareholders will soon realize something is wrong. Soon a year of silence and it's being paraded around as it suits the swindlers. I wonder if we close at 12.6 today? That silence could well end in a price much lower if something or someone doesn't intervene, tragic that one can push it down 60% on nothing. Now one has to go down to minus 3% to sell a small portion.
- ·12.8.Saniona is facing an exciting future with all internal study starts, external study starts, and a platform that more or less churns out good candidates. The coming 2-3 years will be very interesting, but also the months.
- ·10.8.0-1% up at close today 🤣🤣🤣🤣Oh well - it should make a good move up today, on that news, I would think - but alas, the market's ways are unfathomable :)
- ·10.8. · MuokattuSaniona has the right to receive development, regulatory, and commercial milestone payments of up to 172 million USD, consisting of up to 97 million USD in development and regulatory milestones and up to 75 million USD in commercial milestones. In addition to this, Saniona has the right to tiered royalty payments on the net sales of the products that AstronauTx commercializes within the framework of the collaboration.Precisely, and here Redeye writes.... Saniona announced this morning that AstronauTx has exercised its option under the 2023 research collaboration and option agreement, securing "exclusive worldwide rights" to research, develop, manufacture and commercialize therapeutic candidates arising from the collaboration. The program has produced the development candidate ATX0926, which is expected to enter IND-enabling studies shortly and where the aim is, according to AstronauTx, "promoting glymphatic flow as a potential new approach to treating neurological disease." As compensation, Saniona receives shares in AstronauTx with a value of USD5m, priced on the terms of the Series A financing completed in October 2023. Saniona is eligible for milestones of up to USD172m, comprising up to USD97m in development and regulatory milestones and up to USD75m in commercial milestones, in addition to tiered royalties on net sales. Although it has taken some time, it is our view that the exercise is a positive development and a further strong validation of Saniona's ion channel platform. AstronauTx is backed by investors including Novartis Venture Fund, Bristol Myers Squibb and EQT Life Sciences, in other words, very strong backers. Saniona does not receive cash directly at this stage, but it retains the right to significant milestones and royalties should the program advance, and the shareholding gives it a second way to gain value from the collaboration (and potentially other AstronauTx programs). As we have said before, there is considerable value in Saniona's platform, and the company now holds a stake in another interesting venture. We make no immediate change to our valuation at this stage (we currently have a valuation of the collaboration in our SOTP), but will discuss the news and review the implications further in our Q2 update and investor call.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt